Run the checker

State filing guide

CLIA waiver application and requirements in Utah.

Ask about my application — no payment today

Utah's ownership disclosure separates an initial disclosure from a change of ownership and asks an authorized representative to attest.

Sources checked 2026-11-04 · next source check due 2026-12-04

Additional application documents

These findings describe the linked sources. They do not establish that your facility qualifies for an exemption or that its application is ready. Facility type, ownership, personnel, locations and exact test systems can change the requirements.

We do not prepare Utah applications yet

Leave your email and we will write to you once, when we start taking Utah cases.

Waitlist request for Utah

Business details only. Do not enter patient information or government identifiers.

What the official sources say

  • Utah's certification page links CMS-116 and the two-page CLIA Ownership & Controlling Interest Disclosure Statement. The linked disclosure is marked January 2004; its presence on the state page does not establish that every new waived-only laboratory must submit it or that this is the edition the agency will accept for your case.
  • Page 1 has separate Initial Disclosure and Change in Ownership boxes. It asks for the laboratory name, any different DBA, CLIA number, physical and mailing addresses and contact details. For an ownership change, it asks whether there is a new tax ID and, if so, for that number.
  • The disclosure asks for names, addresses and EINs of individuals or organizations with direct or indirect ownership or a controlling interest. It also asks whether any owner held partial or complete ownership of a CLIA laboratory closed by CMS during the previous two years; a yes answer calls for laboratory names and addresses in the page 2 remarks.
  • Page 2 asks for entity type and, if chain-affiliated, the corporation's name, address and EIN. The attestation has fields for the authorized representative's printed name, title, signature and date. It warns that knowingly incomplete or false disclosure can lead to certification denial or termination. The form labels the signer as an authorized representative, without identifying a required clinical credential.

Fees and timing

Check the current agency fee notice and fee schedule. Government fees are separate from preparation-service fees. This source summary does not promise a processing or approval date.

Check my test menu

What still needs confirmation for your facility

  1. 1Before sending an initial application or ownership change, ask labimprovement@utah.gov whether this January 2004 disclosure is required and accepted for that case, which reason box and CLIA-number field apply, and who is authorized to sign. Utah lists email as preferred for program contact; confirm the packet destination and accepted signature format.
  2. 2If the disclosure applies, reconcile the entity, ownership/controlling-interest list, tax-ID change and chain affiliation with the proposed CMS-116, and resolve any prior CMS closure disclosure before the representative signs. This supplement is not evidence of a separate state laboratory license or clearance to test.

Frequently asked questions

What filing route does the cited Utah guidance describe?

Utah's ownership disclosure separates an initial disclosure from a change of ownership and asks an authorized representative to attest.

Which requirements are named in the cited Utah materials?

Utah's certification page links CMS-116 and the two-page CLIA Ownership & Controlling Interest Disclosure Statement. The linked disclosure is marked January 2004; its presence on the state page does not establish that every new waived-only laboratory must submit it or that this is the edition the agency will accept for your case. Page 1 has separate Initial Disclosure and Change in Ownership boxes. It asks for the laboratory name, any different DBA, CLIA number, physical and mailing addresses and contact details. For an ownership change, it asks whether there is a new tax ID and, if so, for that number. The disclosure asks for names, addresses and EINs of individuals or organizations with direct or indirect ownership or a controlling interest. It also asks whether any owner held partial or complete ownership of a CLIA laboratory closed by CMS during the previous two years; a yes answer calls for laboratory names and addresses in the page 2 remarks. Page 2 asks for entity type and, if chain-affiliated, the corporation's name, address and EIN. The attestation has fields for the authorized representative's printed name, title, signature and date. It warns that knowingly incomplete or false disclosure can lead to certification denial or termination. The form labels the signer as an authorized representative, without identifying a required clinical credential.

What do the sources establish about fees and timing in Utah?

Check the current agency fee notice and fee schedule. Government fees are separate from preparation-service fees. This source summary does not promise a processing or approval date.

Does this page confirm CLIA approval or legal compliance in Utah?

No. This is an educational prep checklist. It does not confirm approval, legal compliance, or waived status for any specific device. Verify every requirement with CMS, the FDA, and your state agency before testing.

Other jurisdictions

Each jurisdiction publishes its own terminology, forms, channel, signatures, and fees.

All 52jurisdictions →

Need help with your Utah CLIA route?

Tell us where your clinic operates and what you need to prepare or change. You can ask before you know your exact test system. We review the next facts needed before proposing any paid scope.

Request a scope inquiry — no payment today

Business inquiries only. Do not send patient information, test results, dates of birth, government identifiers, credential numbers, or documents.

Initial business inquiry

From test research to your Utah application

An analyte label does not confirm a device. The exact test system and the clinic’s state route need separate review before a filing scope or price can be confirmed.